Pharmacotherapy of idiopathic parkinson's syndrome with special focus on neuroprotection;Pharmakotherapie des idiopathischen parkinson-syndroms unter besonderer berücksichtigung neuroprotektiver therapiestrategien

Nervenheilkunde

Volumn 20, Issue 4, 2001, Pages 227-236

  Reichmann, H ^a   Sommer, U ^a   Gerlach, M ^a   Riederer, P ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Amantadine; Dopamine agonists; Idiopathic Parkinson syndrome; Neuroprotection; Selegiline

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUPIRTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SCAVENGER; SELEGILINE; UBIQUINONE;

CELL DEATH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; HUMAN; NERVE CELL; NEUROPROTECTION; PARKINSON DISEASE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE CULTURE; TREATMENT PLANNING;

EID: 0034967756     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. 3H)spiperone binding
2. Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats
3. Twenty-five years of amantadine therapy in Parkinson's disease
4. Pharmakotherapie des morbus parkinson. Bericht einer konsensuskonferenz
5. Costs of drug treatment in Parkinson's disease
6. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats
7. 2 and 6-hydroxydopamine
8. The molecular pharmacology of L-deprenyl
9. Neuroprotective therapeutic strategies: Comparison of experimental and clinical results
10. Strategies for the protection of dopaminergic neurons against neurotoxicity
11. Präklinische und klinische aspekte von dopamin-agonisten. Was ist gesichert?
12. Pathophysiologische mechanismen der parkinson-krankheit und neuroprotektive therapiekonzepte
13. Protection of dopaminergic neurons in primary culture by lisuride
14. Lisuride in de novo Parkinson patients: A four year follow-up
15. Lisuride in Parkinson's disease: 4 Year follow-up
16. Altered redox state of platelet coenzyme Q10 in Parkinson's disease
17. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-Dopa-induced dyskinesia
18. Lisurid in der therapie des morbus Parkinson
19. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations
20. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease
21. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel- a human postmortem brain study
22. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study
23. On behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
24. Selegiline as immunostimulant - A novel mechanism of action?
25. Bromocriptine protects mice against 6-hydroxydopamine and scavanges hydroxyl free radicals in vitro
26. Neuroprotection with dopamine agonists
27. The effect of deprenyl and levodopa on the progression of Parkinson's disease
28. Selegiline: Current perspectives on issues related to neuroprotection and mortality
29. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys
30. Effect of deprenyl on the progression of disability in early Parkinson's disease
31. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
32. Effect of lazabemide on the progression of disability in early Parkinson's disease
33. Pramipexole vs. Levodopa as initial treatment for Parkinson disease
34. Apomorphine: An underutilized therapy for Parkinson's disease
35. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
36. SELEDO: A 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa
37. Is ropinirole a selective D2 receptor agonist, neuro-protective in early Parkinson's disease? An (18F) dopa PET study
38. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
39. Early dopamine agonist therapy in Parkinson's disease
40. Kombinationstherapie mit lisurid und L-Dopa in den frühstadien der Parkinson-krankheit verringert und verzögert die entwicklung motorischer fluktuationen. Langzeitstudie über 10 Jahre im vergleich mit einer L-Dopa-monotherapie
41. A new chemical substance in the treatment of Parkinsonís disease
42. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
43. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease